CytomX Therapeutics, Inc. (NASDAQ:CTMX) Given Average Rating of “Moderate Buy” by Brokerages

Shares of CytomX Therapeutics, Inc. (NASDAQ:CTMX) have been assigned an average rating of “Moderate Buy” from the six ratings firms that are presently covering the company, Marketbeat reports. Three investment analysts have rated the stock with a hold rating and three have assigned a buy rating to the company. The average 1 year price objective among brokers that have issued a report on the stock in the last year is $5.77.

Separately, HC Wainwright reissued a “neutral” rating on shares of CytomX Therapeutics in a research report on Tuesday, January 7th.

CytomX Therapeutics Stock Up 0.4 %

NASDAQ CTMX opened at $0.65 on Wednesday. The business’s fifty day simple moving average is $0.87 and its 200-day simple moving average is $1.03. The firm has a market cap of $51.09 million, a PE ratio of 3.84 and a beta of 1.01. CytomX Therapeutics has a 52 week low of $0.60 and a 52 week high of $5.85.

Hedge Funds Weigh In On CytomX Therapeutics

Institutional investors have recently bought and sold shares of the company. FMR LLC grew its position in CytomX Therapeutics by 17.3% in the 3rd quarter. FMR LLC now owns 284,307 shares of the biotechnology company’s stock valued at $335,000 after acquiring an additional 41,949 shares in the last quarter. Geode Capital Management LLC grew its position in CytomX Therapeutics by 4.4% in the 3rd quarter. Geode Capital Management LLC now owns 803,531 shares of the biotechnology company’s stock valued at $948,000 after acquiring an additional 34,032 shares in the last quarter. US Bancorp DE acquired a new position in CytomX Therapeutics in the 3rd quarter valued at about $40,000. Virtu Financial LLC acquired a new position in CytomX Therapeutics in the 3rd quarter valued at about $104,000. Finally, Traphagen Investment Advisors LLC acquired a new position in CytomX Therapeutics in the 4th quarter valued at about $31,000. 67.77% of the stock is owned by institutional investors and hedge funds.

About CytomX Therapeutics

CytomX Therapeutics, Inc, an oncology-focused biopharmaceutical company, focuses on developing novel conditionally activated biologics localized to the tumor microenvironment. The company utilizes conditional activation platform technology for oncology biologics research and development comprising the validation of targets for antibody-drug conjugates (ADCs), opening therapeutic window for novel T-cell engagers (TCEs) targeting solid tumors, and increasing the therapeutic index for immune modulators, such as cytokines; and PROBODY platform in preclinical research in areas outside of oncology.